Secukinumab Vs Adalimumab for the Treatment of Psoriasic Arthritis- a Cost Per Responder Analysis at 48 Weeks from a Peruvian Perspective for Public and Private Health Schemes
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.763
https://www.valueinhealthjournal.com/article/S1098-3015(17)31097-5/fulltext
Title :
Secukinumab Vs Adalimumab for the Treatment of Psoriasic Arthritis- a Cost Per Responder Analysis at 48 Weeks from a Peruvian Perspective for Public and Private Health Schemes
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31097-5&doi=10.1016/j.jval.2017.08.763
First page :
A533
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
728